Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The BC Cancer Foundation is looking to raise $6.8 million to expand its provincial immunotherapy research program, a ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer ...

NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...

This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Marla Milone, a Villanova University School of Business graduate from 2016, has raised nearly $225,000 for cancer research.

BostonGene collaborates with BeiGene to advance biomarker discovery in mantle cell lymphoma: Waltham, Massachusetts Thursday, February 13, 2025, 09:00 Hrs [IST] BostonGene, a lead ...